Genetic Profile and Treatment of NSCLC
We recommend
Kompletní remise ALK-pozitivního karcinomu plic u pacienta po mnoha liniích cílené léčby – kazuistika
Léčba cílená na řídicí onkogenní mutace významně zlepšila výsledky také u pacientů s ALK-pozitivním nemalobuněčným karcinomem plic (NSCLC). V časopisu Frontiers in Oncology byla nedávno publikována kazuistika pacienta s pokročilým onemocněním, u nějž se podařilo dosáhnout úplné remise po několika liniích léčby.
Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
More than 7 years – that is the current median survival of patients with non-small cell lung cancer…
Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report…
Articles on this topic
Progress on Lorlatinib – What's Next?
Lorlatinib is currently mainly used in the 2nd and later lines of treatment for non-small cell…
Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
Interesting real-world data have been brought by a study on the efficacy of lorlatinib in…
Subscribe
Most read on this topic
Journal on this topic
Related topic
Most read on this topic
- Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity
- Progress on Lorlatinib – What's Next?
- Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
- Efficacy of Lorlatinib in Patients with ROS1-Positive NSCLC in Clinical Practice
- Finding Balance Between Intracranial Efficacy and Adverse Effects of ALK Kinase Inhibition
Journal on this topic
Related topic